The push towards proof of concept
We all know that early diagnosis of cancer, and other serious illnesses, can be key to achieving a positive outcome. Nanovery were concerned that although today’s liquid biopsy process is accurate and minimally invasive, it’s also expensive. So it’s not an option for many healthcare providers, who use more traditional methods of diagnosis. Nanovery’s advanced technology reduces both cost and turnaround time for liquid biopsies. Their pioneering project focuses on prostate cancer and liver disease, using nanorobots to capture DNA and RNA and detect cancer-related mutations. But the Nanovery team faced a challenge in moving their ground-breaking work forward. They lacked the necessary resources to conduct laboratory testing and proof-of-concept validation, which was holding them back from getting their innovation to market.